Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Molecular Therapy is Scopus-indexed (Q1, CiteScore 17.9), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Cell Press.
Checked against the index lists dated .
ISSN 1525-0016Verify ISSN ↗1525-0024Verify ISSN ↗
Publisher: Cell Press
Cost to publish: About US$4,500 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Drug Discovery | 5 / 161 | 97th | Q1 |
| Pharmacology | 10 / 328 | 97th | Q1 |
| Genetics | 11 / 357 | 97th | Q1 |
| Molecular Biology | 25 / 414 | 94th | Q1 |
| Molecular Medicine | 13 / 179 | 93rd | Q1 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2000–present, best quartile Q1, CiteScore 17.9.
Molecular Therapy is Q1 in Drug Discovery (rank 5 of 161), Q1 in Pharmacology (rank 10 of 328) and Q1 in Genetics (rank 11 of 357), by CiteScore 2025. It is ranked in 5 subject areas in all.
Molecular Therapy is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 17.9, which places it in quartile Q1 at the 97th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 3.814, quartile Q1, with an H-index of 233.
The publisher lists an article processing charge of about US$4,500 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Molecular Therapy is published by Cell Press. Its print ISSN is 1525-0016 and its online ISSN is 1525-0024.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Molecular Therapy has an h-index of 260 and a 2-year mean of 7.1 citations per paper (OpenAlex). Its Scopus CiteScore is 17.9, quartile Q1. On 2-year citations it ranks #16 of 159 Scopus journals in Drug Discovery.
Molecular Therapy published 607 papers in 2025. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 89 research articles (2026), authors are most often from United States (34.2%), China (16.9%) and United Kingdom (7.3%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 68 retracted papers are recorded (3 per 1,000 papers). The Problematic Paper Screener flags 4 of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.